Customize your JAMA Network experience by selecting one or more topics from the list below.
Androgen deprivation therapy is often used as an adjunct to surgery or radiation for patients with high-risk prostate cancer. However, some evidence suggests that patients with localized prostate cancer are receiving primary androgen deprivation therapy (PADT) as an alternative to surgery, radiation, or conservative management. In a population-based cohort study of men aged 66 years or older and who did not receive definitive local therapy for clinical stage T1-T2 prostate cancer, Lu-Yao and colleagues assessed the relationship between PADT and conservative management and prostate cancer–specific survival or overall survival. The authors report that PADT was associated with worse 10-year prostate cancer–specific survival and no improvement in overall survival compared with conservative management.
This Week in JAMA . JAMA. 2008;300(2):141. doi:10.1001/jama.2008.42
Create a personal account or sign in to: